Citations

Showing 10 of 108119 citations.

Impact of preoperative sarcopenia in patients undergoing sacral tumor resection
Brinkmann, Elyse J. , Wenger, Doris E. , Johnson, Joshua D. , Karim, Syed M., Blezek, Daniel J. , Rose, Peter S. , Houdek, Matthew T. , Houdek, Matthew T

Mayo Clinic

Journal of Surgical Oncology | December 21, 2021 | Volume: 125 | Issue: 4 | Pages: 790-795

10.1002/jso.26776 | PMID 34932215 Get It

AbstractIntroductionSacral tumor resection is known for a high rate of complications. Sarcopenia has been found to be associated with wound complications; however, there is a paucity of data examining the impact of sarcopenia on the outcome of sacral tumor resection.MethodsForty‐eight patients (31 primary sarcomas, 17 locally recurrent carcinomas) undergoing sacrectomy were reviewed. Central sarcopenia was assessed by measuring the psoas:lumbar vertebra index (PLVI), with the 50th percentile (0.97) used to determine which patients were high (>0.97) versus low (<0.97).ResultsTwenty‐four (50%) patients had a high PLVI and 24 (50%) had a low PLVI (sarcopenic). There was no difference (p > 0.05) in the demographics of patients with or without sarcopenia. There was no difference in the incidence of postoperative wound complications (odds ratio [OR] = 1.0, p = 1.0) or deep infection (OR = 0.83, p = 1.0). Sarcopenia was not associated with death due to disease (hazard ratio [HR] = 2.04, p = 0.20) or metastatic disease (HR = 2.47, p = 0.17), but was associated with local recurrence (HR = 6.60, p = 0.01).ConclusionsCentral sarcopenia was not predictive of wound complications or infection following sacral tumor resection. Sarcopenia was, however, an independent risk factor for local tumor recurrence following sacrectomy and should be considered when counseling patients on the outcome of sacrectomy.
Probiotic Bifidobacterium breve Prevents Memory Impairment Through the Reduction of Both Amyloid-β Production and Microglia Activation in APP Knock-In Mouse
Abdelhamid, Mona, Zhou, Chunyu, Ohno, Kazuya, Kuhara, Tetsuya, Taslima, Ferdous, Abdullah, Mohammad, Jung, Cha-Gyun, Michikawa, Makoto, Abdelhamid, Mona , Zhou, Chunyu, Ohno, Kazuya, Kuhara, Tetsuya, Taslima, Ferdous, Abdullah, Mohammad, Jung, Cha-Gyun, Michikawa, Makoto

Mayo Clinic

Journal of Alzheimer’s Disease | December 21, 2021 | Volume: 85 | Issue: 4 | Pages: 1555-1571

10.3233/jad-215025 | PMID 34958017 Get It

Background: Probiotic supplementation reestablishes microbiome diversity and improves brain function in Alzheimer’s disease (AD); their molecular mechanisms, however, have not yet been fully illustrated. Objective: We investigated the effects of orally supplemented Bifidobacterium breve MCC1274 on cognitive function and AD-like pathologies in App NL- G- F mice. Methods: Three-month-old App NL- G- F mice were orally supplemented with B. breve MCC1274 for four months. The short-term memory function was evaluated using a novel object recognition test. Amyloid plaques, amyloid-β (Aβ) levels, Aβ fibril, amyloid-β protein precursor and its processing enzymes, its metabolic products, glial activity, and cell proliferation in the subgranular zone of the dentate gyrus were evaluated by immunohistochemistry, Aβ ELISA, western blotting, and immunofluorescence staining. The mRNA expression levels of pro- and anti-inflammatory cytokines were determined by qRT-PCR analysis. Results: We found that the oral B. breve MCC1 274 supplementation prevented memory impairment in App NL- G- F mice and decreased hippocampal Aβ levels through the enhancement of the a-disintegrin and metalloproteinase 10 (ADAM10) level. Moreover, administration of the probiotic activated the ERK/HIF-1 α signaling pathway responsible for increasing the ADAM10 level and also attenuated microglial activation, which in turn led to reduction in the mRNA expression levels of pro-inflammatory cytokines in the brain. In addition, B. breve MCC1274 supplementation increased the level of synaptic proteins in the hippocampus. Conclusion: Our findings support the possibility that oral B. breve MCC1274 supplementation might be used as a potential preventive therapy for AD progression.
Faculty Opinions recommendation of Fumarate is a terminal electron acceptor in the mammalian electron transport chain.
Maher, Jim

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | December 21, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.741260846.793590485 Get It

Intensive Care Unit Sedation Practices at a Large, Tertiary Academic Center
Hofer, Mikaela M., Wieruszewski, Patrick M. , Nei, Scott D. , Mara, Kristin C. , Smischney, Nathan J. , Mara, Kristin, Mara, Kristin C , Wieruszewski, Patrick M , Smischney, Nathan J , Nei, Scott , Hofer, Mikaela

Mayo Clinic

Journal of Intensive Care Medicine | December 21, 2021 | Volume: 37 | Issue: 10 | Pages: 1383-1396

10.1177/08850666211067515 | PMID 34931884 Get It

Background Sedatives are frequently administered in an ICU and are often dependent on patient population and ICU type. These differences may affect patient-centered outcomes. Objective Our primary objective was to identify differences in sedation practice among three different ICU types at an academic medical center. Methods This was a retrospective cross-sectional study of adult patients (≥18 years) requiring a continuous sedative for ≥6 h and admitted to a medical ICU, surgical ICU, and medical/surgical ICU at a single academic medical center in Rochester Minnesota from June 1, 2018 to May 31, 2020. We extracted baseline characteristics; sedative type, dose, and duration; concomitant therapies; and patient outcomes. Summary statistics are presented. Results A total of 2154 patients met our study criteria (1010 from medical ICU, 539 from surgical ICU, 605 from medical/surgical ICU). Propofol was the most frequently used sedative in all ICU settings (74.1% in medical ICU, 53.8% in surgical ICU, 68.9% in medical/surgical ICU, and 67.5% in all ICUs). The mortality rate was highest in the medical/surgical ICU (40.2% in medical ICU, 26.0% in surgical ICU, 40.7% in medical/surgical ICU, and 36.8% in all ICUs). 90.7% of all patients required mechanical ventilation (92.9% in medical ICU, 88.5% in surgical ICU, and 89.1% in medical/surgical ICU). Overall, patients spent more time in light sedation than deep sedation, 75% versus 10.3%, during their ICU admission. Patients in the medical ICU spent a greater proportion of time positive for delirium than the other ICU settings (35.7% in medical ICU, 9.8% in surgical ICU, and 20% in medical/surgical ICU). Similar amounts of opioids (morphine milligram equivalents) were used during the continuous sedative infusion between the three settings. Conclusions We observed that patients in the medical ICU spent more time deeply sedated with multiple agents which was associated with a higher proportion of delirium.
Transcatheter Nonductal Reverse Potts Shunt Creation in Pulmonary Arterial Hypertension
Anderson, Jason H. , Frantz, Robert P. , Cajigas, Héctor , Cabalka, Allison K. , Frantz, Robert P , Cajigas, Hector R , Taggart, Nathaniel W , Anderson, Jason , Taggart, Nathaniel W.

Mayo Clinic

Circulation: Cardiovascular Interventions | December 21, 2021 | Volume: 15 | Issue: 1 | Pages: No page available

10.1161/circinterventions.121.011315 | PMID 34930014 Get It

Novel Use of a Synovis™ Coupler device for a Surgical Lymphovenous Anastomosis for the treatment of refractory Chylothorax in a patient with Central Lymphatic Flow Disorder.
Rezkalla, Joshua , Husain, Majid, Slack, Ginger, Sinha, Sanjay , Rezkalla, Josh

Mayo Clinic

No container title available | December 21, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.164009788.87584871/v1 Get It

Refractory post-operative chylothorax in congenital heart disease is difficult to treat. We present a case of intractable neonatal chylothorax after cardiac surgery due to central lymphatic flow disorder that was treated by creating a lymphovenous anastomosis of the thoracic duct to the left external jugular vein for definitive treatment
Advances in Predictive Modeling Using Machine Learning in the Field of Hepatology
Kezer, Camille A. , Shah, Vijay H. , Simonetto, Douglas A. , Simonetto, Douglas A , Kezer, Camille

Mayo Clinic

Clinical Liver Disease | December 21, 2021 | Volume: 18 | Issue: 6 | Pages: 288-291

10.1002/cld.1148 | PMID 34976373 Get It

GNE myopathy: Don't sleep on the platelets
Beecher, Grayson , Liewluck, Teerin , Liewluck, T , Beecher, Grayson

Mayo Clinic

Muscle & Nerve | December 21, 2021 | Volume: 65 | Issue: 3 | Pages: 263-265

10.1002/mus.27477 | PMID 34931325 Get It

See article on pages 284–290 in this issue.
Arrhythmia Variant Associations and Reclassifications in the eMERGE-III Sequencing Study
Glazer, Andrew M. , Davogustto, Giovanni , Shaffer, Christian M., Desai, Reshma R. , Farber‐Eger, Eric , Dikilitas, Ozan , Shang, Ning , Muhammad, Ayesha , Shaffer, Lauren Lee, Kalash, Olivia R., Bland, Harris T. , Yoneda, Zachary T. , Mitchell, Devyn , Kroncke, Brett M. , Jarvik, Gail P. , Gordon, Allan , Larson, Eric B. , Manolio, Teri A. , Luo, Jonathan Z. , Schaid, Daniel J. , Namjou, Bahram , Singhal, Ashutosh , Liu, Cong , Ralston, James D. , Leppig, Kathleen A. , Håkonarson, Håkon , Sleiman, Patrick , Sohn, Sunghwan , Network, the eMERGE, Denny, Joshua C. , Wei, Wei‐Qi, Shoemaker, M. Benjamin , Roden, Dan M. , Ralston, James D. , Farber-Eger, Eric H , Dikilitas, Ozan , Mosley, Jonathan D , Van Driest, Sara L , Wells, Quinn S , Wada, Yuko , Yoneda, Zachary T , Kroncke, Brett M , Kullo, Iftikhar J , Jarvik, Gail P , Gordon, Adam S , Manolio, Teri A , Mirshahi, Tooraj , Schaid, Daniel, Alsaied, Tarek , Hripcsak, George , McNally, Elizabeth M , Sohn, Sunghwan , Glessner, Joseph , Wei, Wei-Qi , George, Alfred L , Shoemaker, M Benjamin , Roden, Dan M. , Hakonarson, Hakon , Denny, Joshua C , Bland, Sarah T , Liu, Cong , Glazer, Andrew M , Vanoye, Carlos G. , Pacheco, Jennifer A. , Yang, Tao , Driest, Sara L. Van , Wells, Quinn S. , Wada, Yuko , Kullo, Iftikhar J. , Singh, Rajbir , Weng, Chunhua , McNally, Elizabeth M. , Chung, Wendy K. , Carrell, David , Network, the eMERGE, George, Alfred L.

Mayo Clinic

Circulation | December 21, 2021 | Volume: 145 | Issue: 12 | Pages: 877-891

10.1161/circulationaha.121.055562 | PMID 34930020 Get It

Background: Sequencing Mendelian arrhythmia genes in individuals without an indication for arrhythmia genetic testing can identify carriers of pathogenic or likely pathogenic (P/LP) variants. However, the extent to which these variants are associated with clinically meaningful phenotypes before or after return of variant results is unclear. In addition, the majority of discovered variants are currently classified as variants of uncertain significance, limiting clinical actionability. Methods: The eMERGE-III study (Electronic Medical Records and Genomics Phase III) is a multicenter prospective cohort that included 21 846 participants without previous indication for cardiac genetic testing. Participants were sequenced for 109 Mendelian disease genes, including 10 linked to arrhythmia syndromes. Variant carriers were assessed with electronic health record–derived phenotypes and follow-up clinical examination. Selected variants of uncertain significance (n=50) were characterized in vitro with automated electrophysiology experiments in HEK293 cells. Results: As previously reported, 3.0% of participants had P/LP variants in the 109 genes. Herein, we report 120 participants (0.6%) with P/LP arrhythmia variants. Compared with noncarriers, arrhythmia P/LP carriers had a significantly higher burden of arrhythmia phenotypes in their electronic health records. Fifty-four participants had variant results returned. Nineteen of these 54 participants had inherited arrhythmia syndrome diagnoses (primarily long-QT syndrome), and 12 of these 19 diagnoses were made only after variant results were returned (0.05%). After in vitro functional evaluation of 50 variants of uncertain significance, we reclassified 11 variants: 3 to likely benign and 8 to P/LP. Conclusions: Genome sequencing in a large population without indication for arrhythmia genetic testing identified phenotype-positive carriers of variants in congenital arrhythmia syndrome disease genes. As the genomes of large numbers of people are sequenced, the disease risk from rare variants in arrhythmia genes can be assessed by integrating genomic screening, electronic health record phenotypes, and in vitro functional studies. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier; NCT03394859.
Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Reichert, Zachery R. , Kasputis, Tadas, Abusamra, Sophia M. , Kasputis, Amy , Haruray, Saloni , Wang, Yugang , Williams, Shamara , Singhal, Udit , Alva, Ajjai , Cackowski, Frank C. , Caram, Megan E.V. , Palmbos, Phillip L. , Yentz, Sarah , Smith, David C. , Alumkal, Joshi J. , Morgan, Todd M. , Abusamra, Sophia M , Haruray, Saloni , Williams, Shamara , Singhal, Udit , Cackowski, Frank C , Alumkal, Joshi J , Morgan, Todd M , Reichert, Zachery R , Nallandhighal, Srinivas , Palmbos, Phillip

Mayo Clinic

International Journal of Molecular Sciences | December 21, 2021 | Volume: 23 | Issue: 1 | Pages: 4

10.3390/ijms23010004 | PMID 35008431 Get It

The substantial biological heterogeneity of metastatic prostate cancer has hindered the development of personalized therapeutic approaches. Therefore, it is difficult to predict the course of metastatic hormone-sensitive prostate cancer (mHSPC), with some men remaining on first-line androgen deprivation therapy (ADT) for several years while others progress more rapidly. Improving our ability to risk-stratify patients would allow for the optimization of systemic therapies and support the development of stratified prospective clinical trials focused on patients likely to have the greatest potential benefit. Here, we applied a liquid biopsy approach to identify clinically relevant, blood-based prognostic biomarkers in patients with mHSPC. Gene expression indicating the presence of CTCs was greater in CHAARTED high-volume (HV) patients (52% CTChigh) than in low-volume (LV) patients (23% CTChigh; * p = 0.03). HV disease (p = 0.005, q = 0.033) and CTC presence at baseline prior to treatment initiation (p = 0.008, q = 0.033) were found to be independently associated with the risk of nonresponse at 7 months. The pooled gene expression from CTCs of pre-ADT samples found AR, DSG2, KLK3, MDK, and PCA3 as genes predictive of nonresponse. These observations support the utility of liquid biomarker approaches to identify patients with poor initial response. This approach could facilitate more precise treatment intensification in the highest risk patients.